Mar 30, 20211 min
$EQ +10% Ph 1b data. source
$BSGM +6% Awarded US patent. source
$IMAB +6% IND approved for solid tumors. source
$KRYS +5% Complete ph 3 enrollment. source
$FMTX -2% New ph 1 data & ph 2/3 initiation. source
$AMRN +4% EU approval of Vazkepa. source
$CARA +4% EMA accepted MAA for review, decision expected Q2 2022. source